GSK has secured approval in China for Trelegy Ellipta as a maintenance treatment for adults with asthma, adding to its existing indication in COPD and making it the only single inhaler triple therapy ...
The underactive bladder syndrome market is expected to grow steadily, driven by an aging global population and rising ...
Nicotine is a cholinomimetic, similar to the -stigmines and organophosphates. Increase in ACH increases parasympathetic activity from the Nicotinic Receptors. Expect cholinergic toxidrome, but with a ...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage ...
MapLight Therapeutics (MPLT) announced that the U.S. Food and Drug Administration has granted Fast Track designation to ML-007C-MA, an ...
Maplight Therapeutics Inc.’s pricing of a $258.9 million financing this week revived the debate over whether targeting the M1 as well as the M4 muscarinic receptor – as Bristol Myers Squibb Co. does ...
Our approach to treating schizophrenia has changed little for more than half a century. But a shift may be underway, emphasizing novel approaches to the disease and its underlying pathology. This ...
MapLight Therapeutics, a clinical-stage biopharmaceutical company, announced the initiation of a phase 2 study to evaluate the efficacy, safety and tolerability of ML-007C-MA, an investigational novel ...
Neumora Therapeutics, Inc. has announced the initiation of a Phase 1 study for NMRA-861, a potent and selective positive allosteric modulator of the M4 muscarinic receptor, aimed at treating ...
Long-acting muscarinic antagonists (LAMAs), as add-on therapy to inhaled corticosteroids, improved peak forced expiratory volume in 1 second (FEV1) and reduced exacerbations in children younger than ...
This clinical brief is supported by Bristol Myers Squibb and is intended for payers, formulary committees, or other similar individuals or entities with knowledge and expertise in the area of health ...
Nicotine withdrawal induces behavioral symptoms such as tremors and shaking. Suppressing striatal cholinergic interneurons or administering the muscarinic antagonist Procyclidine significantly reduces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results